1. Introduction
===============

The use of real-time PCR in molecular diagnostics has rapidly gained ground and has become the golden standard in many instances, in particular when sensitivity is a concern and quantification is desired, for example, when monitoring the effect of anti-viral treatment ([@bib27], [@bib26], [@bib28], [@bib41]). An additional advantage is that the detection takes place in a homogeneous closed-tube format, which means a significantly reduced risk for carry-over contamination compared to conventional methods ([@bib13]). PCR-based assays are particularly sensitive and robust for detection and quantification of DNA viruses, due to the high conservation of the genomic materials over different strains in combination with the high chemical stability of deoxyribonucleic acids. The remarkable sensitivity of PCR, where a single DNA copy can be detected by an optimized assay, makes the extraction procedure the limiting factor in the diagnostic setting rather than the PCR-coupled detection step ([@bib12], [@bib33], [@bib43]). However, even if nucleic acid extraction has been successful there are several ways by which the PCR amplification/detection step may fail. Among these are: (i) the target for primers and/or probe may not be conserved (particularly relevant in infectious disease diagnostics) ([@bib15], [@bib30]), (ii) the fluorescent probes used in real-time PCR are frequently chemically unstable and may be degraded.

2. The LightUp^®^ probe
=======================

Recently, the LightUp^®^ probe was constructed to alleviate these drawbacks encountered in PCR based diagnostics ([@bib39], [@bib40], [@bib22]). This is accomplished by the use of a fluorescent reporter dye that is coupled to an oligomer of the DNA analogue peptide nucleic acid (PNA) by a flexible linker ([Fig. 1](#fig1){ref-type="fig"} ). PNA is an uncharged isomorphous DNA mimic composed of *N*-(2-aminoethyl)glycine subunits ([@bib29]) that provides strong but still specific binding and serves as the sequence recognizing element of the probe. In fact, PNA has the remarkable property of exhibiting higher sequence specificity, in terms of melting point decrease, when bound to DNA than DNA itself ([@bib10]). Shorter probes can be used with the LightUp^®^ Probe technology than with most competing DNA based probe technologies ([@bib25], [@bib42], [@bib4], [@bib27]). This is due to the high binding affinity of PNA that is further augmented by the dye interaction with DNA. Thus, conserved patches can be found more easily in highly varying microbial or viral genomes. In this respect LightUp probes resemble TaqMan^®^ minor groove binding (MGB) probes ([@bib2]). The fluorophor used in LightUp^®^ probes is an asymmetric cyanine dye that fluoresces when the probe binds its target DNA but is virtually non-fluorescent when the probe is free in solution. One example is thiazole orange shown in [Fig. 1](#fig1){ref-type="fig"}. Other examples are the SYBR Green proprietary dye from Molecular probes Inc (Oregon, USA), and the BOXTO dye ([@bib19], [@bib18]) that is shown in [Fig. 2](#fig2){ref-type="fig"} . The use of PNA is important. Since the dye is positively charged, a significantly higher background signal would result from internal binding of the dye if DNA was used instead of PNA ([@bib38]). This class of fluorescent dyes are also relatively stable and the ReSSQ^®^ kits that are based on the LightUp^®^ probe can be stored in the fridge rather than the freezer storage typical for other PCR kits. These dyes in combination with the PNA backbone, which is degraded by neither nucleases nor proteases ([@bib7]), amounts to very stable probes and robust assays. To further improve the stability of the ReSSQ^®^ product line the nucleic acids standard materials are provided lyophilized.Fig. 1A LightUp^®^ probe with Tiazole Orange (TO) as the fluorescent dye.Fig. 2Structure of the BOXTO dye.

DNA based sequence recognizing fluorescent probes usually utilize fluorophor quencher pairs that are separated during the amplification process. TaqMan^®^ probes are degraded by the 5′-nuclease activity of the DNA polymerase which releases the fluorophor from its sequence recognizing element, and thereby separates it from the quencher so that fluorescence emission can occur ([@bib25]). Molecular Beacons achieve the same goal by a rearrangement of the secondary structure upon hybridization, which causes a separation of the quencher and the fluorophor ([@bib42]). Fluorescence resonance energy transfer (FRET) probes work slightly differently. Instead of the acceptor dye functioning as a quencher, it emits the detectable fluorescence when the two probes bind adjacent to each other on the target DNA molecule ([@bib4]). The LightUp^®^ Probe works by a different mechanism. The probe has only a single asymmetric cyanine dye. This type of dye releases the excitation energy by internal motion when free in solution and is under these conditions virtually non-fluorescent and hence it is self-quenched. When bound to DNA, however, the dye becomes brightly fluorescent due to motional hindrance in the bound state ([@bib39]).

3. Diagnosing cytomegalovirus with LightUp^®^ probes
====================================================

Immunosuppressed transplant recipients as well as persons infected with human immunodeficiency virus type 1 (HIV-1) are susceptible to severe cytomegalovirus (CMV) infections. Furthermore, congenital CMV infection with high morbidity rate is common. It is therefore important to detect this condition in clinical practice.

In transplant recipients, CMV load is used as an indicator of active CMV disease and for monitoring the effect of anti-viral treatment ([@bib28], [@bib17], [@bib41]). In HIV patients, the risk of developing CMV disease has been reported to be directly related to the quantity of CMV in the plasma ([@bib35], [@bib34]).

Several commercial test are available, e. g. the COBAS AMPLICOR^®^ CMV MONITOR Test (Roche Diagnostics), the Hybrid Capture^®^ System CMV DNA test (Digene Corp.) and the NucliSens® CMV pp67 assay (bioMérieux). Although all these tests are very useful, in-house so-called home-brew real-time PCR assays have come to increasing use. The main reasons are the superior sensitivity of PCR, the closed tube format of real-time PCR, which minimizes the risk for cross-over contamination, and the possibility of reproducible and precise viral load quantifications, as outlined above. However, the results from home-brew assays are often not reproducible between laboratories and there is consequently a need for standardization.

The ReSSQ^®^ Assays (LightUp Technologies, Huddinge, Sweden) is a new line of commercial kits for qualitative and quantitative detection of viral DNA in clinical samples that tries to bridge this gap and provide a standardized test built on the LightUp^®^ probe technology. In real-time PCR applications quantification is obtained by comparing the PCR cycle at which the fluorescence reaches a certain threshold level for the unknown clinical sample with the PCR threshold cycles values from a sequential (usually 10 fold) dilution series of the standard DNA. In [Fig. 3](#fig3){ref-type="fig"} the dynamic range and reproducibility of the ReSSQ^®^ CMV Assay is illustrated from the standard curve obtained in quadruplicates and repeated in two runs. The slopes of −3.344 and −3.276 corresponds to essentially 100% PCR reaction efficiency (−3.322). The standard curves are perfectly linear in standard curve interval of 10^2^--10^9^ copies/PCR ([@bib45]).Fig. 3Dynamic range of the ReSSQ^®^ CMV Assay. Serial dilutions of CMV DNA were analyzed in quadruplicates and the threshold cycle number (*C*~t~) was plotted against the log CMV DNA copy number. Values from two separate experiments, indicated as gray and black boxes and lines respectively. The regression line was obtained by least-square fitting.

The Quality Control for Molecular diagnostics (QCMD) initiative ([@bib44]) serves to provide a reference for comparison between different diagnostics labs as well as commercial kit manufacturers. To this end QCMD designs and develops quality control materials and proficiency programmes. In [Table 1](#tbl1){ref-type="table"} (reproduced from [@bib45]) the quantification of the QCMD CMV proficiency panels of 2002 and 2003 obtain by using the ReSSQ^®^ CMV assay are shown. The viral loads measured by the ReSSQ^®^ assay are close to the QCMD target values on both panels with an average deviation of only 23%. Furthermore, all negative controls are confirmed without false-positive results. Zweygberg Wirgart and collegues did also use the ReSSQ^®^ assay to monitor the effect of anti-varial treatment and compared the results with those obtained with the AMPLICOR CMV MONITOR assay (Roche Diagnostics). The CMV DNA load was monitored in one allogeneic bone marrow-transplanted patient during a period of 175 days ([Fig. 4](#fig4){ref-type="fig"} ). After 2 months of prophylactic Valtrex therapy with very low or undetectable CMV DNA levels, the viral load increased significantly at day 65 and continued to rise, as determined by both assays. The patient was therefore treated with Cymevene from day 74, but did not respond, and as resistance to ganciclovir was suspected the patient was switched to Foscavir therapy on day 87. Ganciclovir resistance was indeed verified subsequently. The high CMV viral loads were successfully suppressed by the Foscavir therapy, but as the drug was not well tolerated by the patient, therapy was interrupted. Increasing levels of CMV was again detected at day 153 by both assays, and suppressed after a second Foscavir treatment. The course of events is clearly reflected in the viral load determinations and both methods yield closely similar results. This shows that the ReSSQ^®^ assay is a highly useful tool for CMV viral load monitoring ([@bib45]).Table 1CMV DNA load in QCMD CMV panel 2002 and 2003 measured by ReSSQ^®^ CMV AssaySample numberCopies/mlQCMD-ReSSQ Diff LogQCMDReSSQCMV2002-2640013 600−0.3CMV2002-1264009200−0.2CMV2002-6500032000.1CMV2002-816006000.4CMV2002-4125010000.1CMV2002-14001240−0.5CMV2002-10400800−0.3CMV2002-11313392−0.1CMV2002-3100 (±)NegativeCMV2002-978 (±)NegativeCMV2002-5NegativeNegativeCMV2002-7NegativeNegativeCMV2003-331 25014 2000.3CMV2003-1031 25020 7000.2CMV2003-5625030200.3CMV2003-12625035500.2CMV2003-412503310.6CMV2003-112506540.3CMV2003-22501450.2CMV2003-72501130.3CMV2003-950 (±)60−0.1CMV2003-1150 (±)NegativeCMV2003-6NegativeNegativeCMV2003-8NegativeNegativeFig. 4CMV DNA load change obtained by the COBAS AMPLICOR CMV assay (black) and the ReSSQ CMV^®^ Assay (white) in an allogeneic bone marrow-transplant patient who had received Valtrex, Cymvene and Foscavir therapy. Boxes indicate the time period of antiviral therapy. For clarity, the time axis is not drawn to scale.

4. Diagnosing SARS coronavirus with LightUp^®^ probes
=====================================================

Severe acute respiratory syndrome coronavirus (SARS-CoV), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the family *Coronaviridae* ([@bib9], [@bib32]). It was first identified during the fall of 2002 in the Guangdong Province in China and the epidemic of SARS in 2003 has affected 30 countries, with 8098 cases and 774 death reported ([@bib24]). The severity of the disease combined with its rapid spread and lack of specific treatment requires the development of fast and sensitive diagnostic assay ([@bib8]).

A ReSSQ^®^ assay was developed for detection of specific SARS-CoV genes. This assay was used in collaboration with Swedish Institute for infectious disease control to investigate if nitric oxide (NO) inhibits the replication cycle of SARS-CoV ([@bib3]). Nitric oxide is an important signalling molecule between cells and has been shown to have an inhibitory effect on some viruses ([@bib1], [@bib21], [@bib31], [@bib5], [@bib6]).

To investigate if NO inhibits the viral RNA replication process of SARS-CoV, Vero E6 cells were infected with SARS-CoV at M.O.I 0,1. At 1 h.p.i, the cells were treated with 400 μM of the organic NO donor S-Nitroso-*N*-acetylpenicillamine (SNAP) or, as a negative control, with *N*-acetylpenicillamine (NAP), which lacks the NO-donating S-nitroso group, lysed by TRIZOL at different periods of time and total RNA was isolated. The viral RNA was subsequently quantified by Real-time PCR using the ReSSQ^®^ SARS assay (LightUp, Technologies AB, Stockholm, Sweden) on a LightCycler 1.0 instrument (Roche Diagnostics, Basel, Switzerland). Quantified armored SARS RNA (CoV-NC), containing the nucleocapsid gene, from Ambion diagnostics was used as a quantification standard ([@bib11]). RNA was used to synthesize cDNA with the SuperScript III RNase H-reverse transcriptase system.

The ReSSQ^®^ SARS assay have been used in [Fig. 5](#fig5){ref-type="fig"} to amplify and detect a sequential dilution from 0.5 to 25 000 copies/PCR of the Ambion armored RNA standard. It can be seen that all three replicates at the 0.5 copies/PCR level are readily detected which illustrates the excellent sensitivity of the assay. Furthermore, when a standard curve is calculated from the dilution data the PCR efficiency calculated from the slope of the standard curve is close to 100% ([Fig. 5](#fig5){ref-type="fig"}).Fig. 5Sensitivity of a LightUp probe system SARS-CoV NC. (A) Detection of the quantitation standards (SARS-CoV NC, Ambion). The copy number (copies/PCR) are indicated, NTC is the non-template control (negative control). (B) Standard curve: slope −3.465 and intercept 32.2.

The specificity of the assay was further investigated by using extracted RNA from several viruses known to cause similar clinical symptoms as template. From the results displayed in [Fig. 6](#fig6){ref-type="fig"} it can be concluded that the ReSSQ^®^ SARS assay does not cross-react with any of the tested viruses.Fig. 6Specificity of the ReSSQ^®^ SARS assay. The specificity was tested against viral RNA of the types indicated. Fifty copies of SARS corona virus were used as positive control.

Finally, in [Fig. 7](#fig7){ref-type="fig"} (Reproduced from [@bib3]) it is shown that 400 μM of the NO-donor SNAP significantly inhibits the viral RNA production but that 400 μM of NAP has no such effect. This result provides evidence that NO inhibits the SARS Coronavirus and also illustrates the utility of the ReSSQ^®^ SARS assay in viral load monitoring of an RNA virus.Fig. 7SNAP blocks the viral RNA replication of SARS-CoV. The Vero E6 cells were infected at an M.O.I. of 0.1 and treated with 400 μM SNAP (●) or NAP (○) at 1 h.p.i. Treated cells were lysed by TRIZOL at different periods of time as indicated and the viral RNA quantified as described in the text.

5. Diagnosing lymphoma with LightUp^®^ probes
=============================================

In most real-time PCR applications disease is monitored by measuring the expression of a marker gene relative to that of a reference gene that is expected to be expressed at a level that is independent of disease state and that is also unaffected by other parameters that may vary among the patients. Today reference genes are selected from optimized reference gene panels such as the Human Endogenous Control Gene Panel from TATAA Biocenter ([www.tataa.com](http://www.tataa.com)). Still, even properly selected reference genes usually show some variation among samples that add to experimental uncertainty in diagnosis. Using the LightUp^®^ probes we developed an alternative approach to detect and monitor disease by real-time PCR that does not rely on the stable expression of reference genes ([@bib36]). Instead of measuring the relative expression of a marker gene to a reference gene, we propose measuring the relative expression of two marker genes that are reciprocally affected by the disease condition. One disease for which this approach is applicable is Non-Hodgkin lymphoma (NHL). NHL develops from the B-lymphocytic lineage and the B-lymphocytes produce immunoglobulins with a heavy chain and either a kappa (IgL*κ*) or a lambda (IgL*λ*) light chain ([Fig. 8](#fig8){ref-type="fig"} ). Each B-lymphocyte decides early in its development which light chain to produce. In healthy humans about 60% of the B-cells produce kappa chains and 40% produce lambda chains. Hence, in normal lymphoid tissue that contains a mixture of B-cells a IgL*κ*:IgL*λ* expression ratio of about 60:40 is expected ([@bib23]). Lymphomas, like all malignant tumors, are clonal and arise from one transformed cell. Lymphoma tissues are dominated by the tumor cells and consequently the IgL*κ*:IgL*λ* ratio is changed. Kappa-producing tumors result in a higher IgL*κ*:IgL*λ* ratio, while lambda-producing tumors result in a lower ratio than 60:40.Fig. 8Schematic drawing of an antibody.

5.1. Sample preparation
-----------------------

Surgical lymph node biopsies from previously untreated patients were transported from the operation theatre in ice water-chilled boxes and handled in the laboratory within 30 min. Material for the study was rapidly frozen in dry ice/isopentane and stored at −70 °C. Fine needle aspirates were suspended in RNAlater (Ambion) directly at the time of sample collection. The cell suspension was stored in RNAlater at 4 °C for one or two days before the cells were collected by centrifugation and stored frozen at −80 °C. Parts of the tissues were fixed in formalin and used for routine diagnostic analysis. Diagnosis was reached by a combination of microscopic evaluation of histology, immunostaining of several markers including those for the kappa and lambda chains (IHC), and in some cases flow cytometry. The samples were classified as lymphadenitis or malignant lymphoma according to the Revised European-American lymphoma (REAL) classification ([@bib14]).

5.2. RNA extraction and cDNA analysis
-------------------------------------

RNA was extracted using the Fast Prep System (FastRNA Green, Qbiogene). Ten micrograms of total RNA was mixed with 2 μg of pdT oligomers (Pharmacia) and incubated at 65 °C for 5 min. First strand cDNA synthesis was then performed by adding 0.05 mol/l Tris--HCl, pH 8.3, 0.075 mol/l KCl, 3 mmol/l MgCl~2~, 0.01 mol/l DTT, 10 U/ml M-MLV reverse transcriptase (Life Technologies), 0.05 U/mL RNA guard (Life Technologies) and 10 mmol/l of each deoxyribonuleotide (Life Technologies) to a final volume of 20 μl and incubating the samples at 37 °C for 1 h. The reaction was terminated by incubation at 65 °C for 5 min and samples were stored at −80 °C.

5.3. LightUp^®^ probes and PCR
------------------------------

Two LightUp probes, H-CCTTTTTCCC-NH~2~ (IgL*κ*LUP) and CCTCCTCTCT-NH~2~ (IgL*λ*LUP), directed against PCR amplification products of the constant regions in the human immunoglobulin kappa (IgL*κ*) and lambda (IgL*λ*) light-chains respectively, were designed. Both probes are homopyrimidine sequences, which are known to exhibit very large signal enhancement upon target binding ([@bib38]). Both probes had the thiazole orange derivate, *N*-carboxypentyl-4-\[(3′-methyl-1′, 3′-benzothiazol-2′-yl) methylenyl\] quinolinium iodide as label attached to the peptide nucleic acid. They were synthesized by solid phase synthesis and purified twice by reverse phase HPLC ([@bib40]). Probe concentrations were determined spectroscopically assuming molar absorptivities at 260 nm of 83 100 (mol/l)^−1^cm^−1^ for IgL*κ*LUP and 81 100 (mol/l)^−1^cm^−1^ for IgL*λ*LUP ([@bib40]). The probes were designed to have melting temperatures of 65--70 °C, which is between the annealing (55 °C) and elongation (74 °C) temperatures of the PCRs. PCR systems were designed for a 231 bp fragment of the human IgL*κ* (GenBank accession number AK024974) and a 223 bp fragment of the human IgL*λ* (GenBank accession number X51755) comprising the IgL*κ*LUP and IgL*λ*LUP target sequences, respectively. Reaction conditions were optimized as described elsewhere ([@bib20]). IgL*κ* and IgL*λ* PCR:s both contained 75 mmol/l Tris (pH 8.8), 20 mmol/l (NH~4~)~2~SO~4~, 0.1% Tween 20, 1 U of JumpStart^TM^ Taq DNA polymerase (with antibody) (Sigma-Aldrich) and 200 ng/μL of Bovine Serum Albumin (Fermentas). Specific components for the IgL*κ* PCR were 5 mmol/l MgCl~2~, 0.2 mmol/l deoxyribonuleotides (Sigma-Aldrich), 800 nmol/l of each primer (MedProbe Inc) and 800 nmol/l IgL*κ*LUP, and for the IgL*λ* PCR 3.5 mmol/l MgCl~2~, 0.4 mmol/l deoxyribonuleotides, 600 nmol/l of each primer and 600 nmol/l IgL*λ*LUP. Primer sequences were for IgL*κ* 5′-TGA GCA AAG CAG ACT ACG AGA-3′ (forward) and 5′-GGG GTG AGG TGA AAG ATG AG-3′ (reverse), and for IgL*λ* 5′-GAG CCT GAC GCC TGA G-3′ (forward) and 5′-ATT GAG GGT TTA TTG AGT GCA G-3′ (reverse).

Real-time PCR was measured in a LightCycler (Roche Diagnostics) using the thermocycler program: 3 min pre-incubation at 95 °C followed by 50 cycles for 0 s at 95 °C, 10 s at 55 °C and 11 s at 74 °C. Fluorescence was monitored at the end of the annealing phase using 470 nm excitation and 530 nm emission (the LightCycler F1 channel). All amplification curves were baseline adjusted by subtracting the arithmetic average of the five lowest fluorescence read-out values in each sample (arithmetic baseline adjustment in the LightCycler software). The threshold was set to a value of 1.00, which was significantly above background noise, and the number of cycles required to reach this level, *C* ~t~, was determined.

5.4. Classification of patient samples
--------------------------------------

Thirty-two patient samples were analyzed for B-cell lymphoma by the LightUp Q-PCR assays. Twenty samples were surgical biopsies and 12 were collected as fine needle aspirates ([@bib36]). All samples were run in duplicates including negative controls. The data are presented in [Fig. 9](#fig9){ref-type="fig"} . In the scatter plot each symbol represents one sample and is positioned in the plot on the coordinate (CT~IgL*κ*~, CT~IgL*λ*~). The corresponding number of cDNA molecules of purified template is indicated in logarithmic scale on the opposite axes. Samples found negative by IHC analysis are shown in green and positive samples are shown in red. The samples above the pink arc are those collected as fine needle aspirates. The relative expression of two genes is given by ([@bib37]):$$\frac{N_{0_{{IgL}\kappa}}}{N_{0_{{IgL}\lambda}}} = K_{RS}\ast\frac{\eta_{{IgL}\lambda}(1 + E_{{IgL}\lambda})^{\mathit{CT}_{{IgL}\lambda} - 1}}{\eta_{{IgL}\kappa}(1 + E_{{IgL}\kappa})^{\mathit{CT}_{{IgL}\kappa} - 1}}$$This can be rearranged into linear form ([@bib36]):$$\mathit{CT}_{{IgL}\kappa} = b\ast\mathit{CT}_{{IgL}\lambda} + m$$Hence, the data points representing negative samples in the scatter plot can be fitted to a straight line that will represent the IgL*κ*:IgL*λ* expression ratio of healthy individuals. The approach does not require the IgL*κ*:IgL*λ* expression ratio to be known. In fact, the estimated ratio of 60:40 is for the IgL*κ*:IgL*λ* light chains, which is the ratio of the protein products. The ratio of the corresponding mRNAs could be different, for example, due to a difference in translation efficiencies of the mRNAs. In the original study the authors estimated the parameters in Eq. [(1)](#fd1){ref-type="disp-formula"} from a detailed characterization of a subset of the samples by in situ calibration ([@bib36]). They found that the IgL*κ*:IgL*λ* mRNA expression ratio of negative samples indeed is close to 60:40, and the authors could also calculate 95% confidence interval for the negative samples. The confidence interval is indicated in the scatter plot by the dashed lines. Hence, negative samples based on QPCR results are expected to be within the dashed lines, while positive samples with *κ* clonality are found below the lines and samples with *λ* clonality are above the lines. The agreement between the QPCR (position in the scatter plot) and IHC (color) classifications is excellent. For the fine needle aspirates, found above the arc in [Fig. 9](#fig9){ref-type="fig"}, the agreement was perfect, even though these samples contained very few cells and therefore not very much mRNA. This very high predictive power of the LightUp probed IgL*κ* vs. IgL*λ* assay demonstrates the strength of designing assays based on relative expression of two reciprocal marker genes instead of comparing expression of a single marker gene with that of a reference gene. Recently, the same strategy was used to diagnose mantle cell lymphoma by measuring the *CCND1*:*CCND3* expression ratio ([@bib16]). The strategy is not limited to two marker genes. Any number of marker genes can be used, and companies such as MultiD Analyses ([www.multid.se](http://www.multid.se)) are developing software to classify samples based on an arbitrary number of marker genes, without relying on reference genes, by identifying characteristic expression patterns.Fig. 9Scatter plot of the expression of the *κ* and *λ* immunoglobulin light chain genes in patient samples. Samples classified as NHL positive by REAL are shown in red, while negative samples are shown in green. The solid line reflects 60:40 IgL*κ*:IgL*λ* expression ratio. The dotted lines indicate 95% confidence interval of negative samples. Samples within the pink arc were collected as fine needle aspirates (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article).

6. Conclusions
==============

The LightUp^®^ probe technology has been shown to be useful for monitoring viral loads both of DNA virus such as the cytomegalovirus and RNA viruses such as the SARS corona virus. The effects of antiviral treatment and nitric oxide are readily detected. It is noteworthy that LightUp^®^ probes are short, typically 8--12 residues, which is very useful in viral diagnostics where the mutation frequency often is high and long conserved regions may be rare. This is particularly true for RNA viruses such as HIV, Influenza and SARS.

A LightUp probe assay has also been shown to quantify the relative expression of the kappa/lambda genes in a way that allows diagnosis of B-lymphocyte monoclonality.
